ANVS · Annovis Bio, Inc.
$1.82
+0.03 (+1.68%)
At close · Aug 21
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management has concluded that substantial doubt exists about the Company's ability to continue as a going concern. Management's plans to mitigate this risk include raising additional capital through equity financings, debt, or other potential alternatives. Management's plans may also include the deferral of certain operating expenses unless and until additional capital is received. However, there can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company, or that the Company will be successful in deferring certain operating expenses. As such, Management has concluded that such plans do not alleviate the aforementioned substantial doubt.”View the 10-Q filed Aug 14, 2026
Market Cap
$76.27M
Shares
42.61M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.82
Open$1.78
Day$1.77–1.84
52W close$1.59–5.10
Avg vol 30d624K
Short int5.2M · 12.2% float · 9.5d
Short vol59%
Last earningsAug 12, 2025
DataJan 2020–Aug 2026
Filing10-Q · Aug 14
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 14, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−27%
below
Price vs 50-day avg
+1%
above
RSI (14)
51
neutral
MACD trend
Positive
52-week position
7%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+10%
trailing
6-month return
−32%
trailing
YTD return
−47%
this year
Relative strength
−43%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+9% holders QoQ · +16 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
12.19% of float · ▼ -4.7% MoM · 9.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
63 holders — near 3-yr high, broad support
Squeeze score
65
elevated · 0–100
Fundamentals
EPS growth
+39%
Y/Y
Balance sheet
$19.5M
net cash
Quant / Vol
risk profile
Volatility
90%
annualized · 1-yr
Max drawdown
−69%
past year
ATR
5.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−27%
Bearish
Price vs 50-day avg
+1%
Bullish
RSI (14)
51
Neutral
MACD trend
Positive
Bullish
52-week position
7%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+9% holders QoQ · +16 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
12.19% of float · ▼ -4.7% MoM · 9.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
63 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $2 · 7%
Range high $5
vs 200-day avg -27%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Parkinson's disease (PD) open-label extension (OLE) study enrollment | 266 | Q2 2026 | — |
| Pivotal Phase 3 Alzheimer's disease (AD) trial enrollment | 850 | Q2 2026 | — |
| granted patents | 40 | year-end 2025 | — |
| patent applications | 48 | year-end 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ANVS
this stock
Annovis Bio, Inc.
|
$76.27M | -47.4% | — | — | 12.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
ARGX
Argenx SE
|
$64.56B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$58.31B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ANVS | -1.6% | +9.6% | -31.8% | +4.0% | -47.4% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +0.3% | +6.3% | -43.0% | +1.9% | -59.2% |
Key facts
CIK
1477845
CUSIP
03615A108
13F (30d)
59 filings
58 filers
Visit website
Investor relations